{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:42:53Z","timestamp":1781066573177,"version":"3.54.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1124\/jpet.119.257576","type":"journal-article","created":{"date-parts":[[2019,4,26]],"date-time":"2019-04-26T19:55:55Z","timestamp":1556308555000},"page":"35-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy"],"prefix":"10.1016","volume":"370","author":[{"given":"Anna Thors\u00f8","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim Vietz","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Asser","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.119.257576_bib1","doi-asserted-by":"crossref","first-page":"E24","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.119.257576_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092042","article-title":"Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias","volume":"9","author":"Andreassen","year":"2014","journal-title":"PLoS One"},{"key":"10.1124\/jpet.119.257576_bib3","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1124\/jpet.119.257576_bib4","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1002\/oby.20805","article-title":"Effect of a test meal on meal responses of satiation hormones and their association to insulin resistance in obese adolescents","volume":"22","author":"Beglinger","year":"2014","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/jpet.119.257576_bib5","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.physbeh.2011.02.015","article-title":"Amylinergic control of food intake in lean and obese rodents","volume":"105","author":"Boyle","year":"2011","journal-title":"Physiol Behav"},{"key":"10.1124\/jpet.119.257576_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.physbeh.2011.04.044","article-title":"Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin","volume":"104","author":"Boyle","year":"2011","journal-title":"Physiol Behav"},{"key":"10.1124\/jpet.119.257576_bib7","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0026-895X(24)08983-1","article-title":"Multiple amylin receptors arise from receptor activity-modifying protein interaction with the calcitonin receptor gene product","volume":"56","author":"Christopoulos","year":"1999","journal-title":"Mol Pharmacol"},{"key":"10.1124\/jpet.119.257576_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/0168-8227(92)90074-2","article-title":"Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance and non-insulin-dependent diabetes mellitus","volume":"15","author":"Enoki","year":"1992","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1124\/jpet.119.257576_bib9","doi-asserted-by":"crossref","first-page":"E821","DOI":"10.1152\/ajpendo.00514.2015","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight","volume":"15","author":"Gydesen","year":"2016","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1124\/jpet.119.257576_bib10","doi-asserted-by":"crossref","first-page":"E598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of the novel dual amylin and calcitonin receptor agonist KBP-089 through dose escalation and combination with a GLP-1 analog","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl 2","key":"10.1124\/jpet.119.257576_bib11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/head.13077","article-title":"Amylin","volume":"57","author":"Hay","year":"2017","journal-title":"Headache"},{"key":"10.1124\/jpet.119.257576_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol Rev"},{"key":"10.1124\/jpet.119.257576_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejphar.2015.05.051","article-title":"KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administration","volume":"762","author":"Hjuler","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.119.257576_bib14","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1124\/jpet.117.241281","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 works as adjunct to metformin on fasting hyperglycemia and HbA1c in a rat model of type 2 diabetes","volume":"362","author":"Hjuler","year":"2017","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.119.257576_bib15","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist KBP-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity (Silver Spring)"},{"key":"10.1124\/jpet.119.257576_bib16","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.119.257576_bib17","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S58459","article-title":"Liraglutide and obesity: a review of the data so far","volume":"9","author":"Ladenheim","year":"2015","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.119.257576_bib18","article-title":"Sustained reduction in food intake and body weight in high-fat-fed rats during 28-day amylin infusion","volume":"52","author":"Mack","year":"2003","journal-title":"Diabetes"},{"key":"10.1124\/jpet.119.257576_bib19","doi-asserted-by":"crossref","first-page":"R1855","DOI":"10.1152\/ajpregu.00297.2007","article-title":"Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight","volume":"293","author":"Mack","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"10.1124\/jpet.119.257576_bib20","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide","volume":"13","author":"Mack","year":"2011","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.119.257576_bib21","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1210\/endo.140.6.6930","article-title":"An amylin receptor is revealed following co-transfection of a calcitonin receptor with receptor activity modifying proteins-1 or -3","volume":"140","author":"Muff","year":"1999","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.257576_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dom.13034","article-title":"A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents","volume":"20","author":"N\u00f8rregaard","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.119.257576_bib23","first-page":"E156","article-title":"Direct plasma radioimmunoassay for rat amylin-(1-37): concentrations with acquired and genetic obesity","volume":"267","author":"Pieber","year":"1994","journal-title":"Am J Physiol"},{"key":"10.1124\/jpet.119.257576_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet Med"},{"key":"10.1124\/jpet.119.257576_bib25","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.119.257576_bib26","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the \u03b2-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.257576_bib27","first-page":"203","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes","volume":"2","author":"Ryan","year":"2009","journal-title":"Drug Des Devel Ther"},{"key":"10.1124\/jpet.119.257576_bib28","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1124\/jpet.119.257576_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/dom.12181","article-title":"A novel long-acting glucose-dependent insulinotropic peptide analogue: enhanced efficacy in normal and diabetic rodents","volume":"16","author":"Tatarkiewicz","year":"2014","journal-title":"Diabetes Obes Metab"},{"key":"10.1124\/jpet.119.257576_bib30","doi-asserted-by":"crossref","first-page":"5657","DOI":"10.1210\/en.2010-0590","article-title":"Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats","volume":"151","author":"Trevaskis","year":"2010","journal-title":"Endocrinology"},{"key":"10.1124\/jpet.119.257576_bib31","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-5491.2007.02333.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus","volume":"25","author":"Vilsb\u00f8ll","year":"2008","journal-title":"Diabet Med"},{"key":"10.1124\/jpet.119.257576_bib32","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1124\/jpet.119.257576_bib33","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1054-3589(05)52006-4","article-title":"Inhibition of gastric emptying","volume":"52","author":"Young","year":"2005","journal-title":"Adv Pharmacol"},{"key":"10.1124\/jpet.119.257576_bib34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/BF00401833","article-title":"Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin","volume":"38","author":"Young","year":"1995","journal-title":"Diabetologia"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259115?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524259115?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.119.257576","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T15:57:45Z","timestamp":1739980665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524259115"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S0022356524259115"],"URL":"https:\/\/doi.org\/10.1124\/jpet.119.257576","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Dual Amylin and Calcitonin Receptor Agonist KBP-088 Induces Weight Loss and Improves Insulin Sensitivity Superior to Chronic Amylin Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.119.257576","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}